The traditional pharmaceutical development pipeline is notoriously slow, expensive, and fraught with attrition. On average, it takes 10–15 years and over $2 billion to bring a single drug from concept to market. Artificial Intelligence is now rewriting this timeline. By streamlining target identification, molecule design, clinical trial planning, and even drug repurposing, AI is radically transforming drug discovery into a faster, smarter, and more precise process. Across the globe, trailblazing companies are demonstrating how AI can shorten drug development cycles and expand therapeutic possibilities, particularly in the face of urgent health challenges.
Sumitomo Dainippon Pharma & Exscientia (UK): The 12-Month Breakthrough
In a groundbreaking collaboration between Japan’s Sumitomo Dainippon Pharma and UK-based Exscientia, the world witnessed the first AI-designed drug candidate—DSP-1181, developed for obsessive-compulsive disorder (OCD). What traditionally takes up to five years in the early-stage discovery process was compressed into just 12 months. Exscientia’s AI platform was used to analyze vast chemical and biological data sets, identifying and optimizing a potent molecule far more rapidly than human-led screening processes. DSP-1181 became the first AI-generated drug to enter clinical trials, setting a global precedent for how AI can turbocharge therapeutic innovation.
Insilico Medicine (US/Hong Kong): AI from Molecule to Clinic
Insilico Medicine, with operations in the US and Hong Kong, is a pioneer in using AI to discover and design novel drugs entirely in silico. Their drug candidate for Idiopathic Pulmonary Fibrosis (IPF)—a fatal and previously underserved lung condition—was identified, validated, and moved to clinical trials in less than 18 months, a feat unheard of in traditional pharmacology. The drug, Rentosertib, was not only AI-discovered but also AI-designed, with algorithms guiding molecular generation, lead optimization, and preclinical assessments. Insilico’s success is emblematic of AI’s disruptive potential in tackling both rare and common diseases.
BenevolentAI (UK) & COVID-19: Rapid Repurposing Amid Crisis
During the COVID-19 pandemic, UK-based BenevolentAI demonstrated the speed and adaptability of AI in drug repurposing. In just three days, the company’s AI platform identified Baricitinib, an existing rheumatoid arthritis drug, as a promising therapeutic candidate for COVID-19. Baricitinib’s anti-inflammatory properties, coupled with its ability to inhibit viral entry, made it a suitable candidate for emergency use. Subsequent clinical trials validated its efficacy, and it was later included in the WHO’s treatment guidelines. This landmark case showed that AI can radically reduce response time during global health emergencies, offering new life to old molecules.
Recursion Pharmaceuticals (US): Rare Diseases, Rapidly Addressed
Recursion Pharmaceuticals, headquartered in the US, has harnessed AI to tackle one of the most complex arenas in medicine: rare genetic diseases. Using a combination of high-throughput imaging, bioinformatics, and machine learning, Recursion rapidly identifies novel drug candidates and their mechanisms of action. A notable example is REC-1245, a potential treatment for a rare genetic disorder, which moved from discovery to IND-enabling studies in under 18 months—less than half the industry average of 42 months. Recursion’s approach exemplifies how AI can create scalable solutions for orphan diseases that are often overlooked due to their limited market size.
These global pioneers illustrate how AI is fundamentally restructuring the pharmaceutical landscape. No longer a theoretical promise, AI is now delivering measurable gains in speed, cost-efficiency, and success rates across drug discovery and development. Whether by identifying entirely new drug candidates or repurposing existing molecules for emergent threats, AI is emerging as the driving force behind a new era of precision, agility, and accessibility in medicine.
–Dr. Devi Sriveni Gangadhar
